期刊文献+

高血压病史及基线血压水平对中国急诊心房颤动患者主要心血管事件的影响 被引量:9

The impact of hypertension history and baseline blood pressure levels on the cardiovascular outcomes in Chinese emergency atrial fibrillation patients
原文传递
导出
摘要 目的 探讨高血压病史及基线血压水平对心房颤动(房颤)患者主要心血管事件(心血管死亡、卒中、心肌梗死和非中枢神经系统栓塞发生)的影响.方法 2008年11月至2011年10月在全国20家医院连续入选急诊就诊的所有房颤患者,无论是否为急诊就诊的主要原因均可入选.记录患者的基线资料、治疗情况;并进行1年随访,记录主要心血管事件(包括心血管死亡、卒中、心肌梗死和非中枢神经系统栓塞事件的发生情况).按照患者既往高血压病史分成二组:高血压病史组和无高血压病史组.应用单变量Cox分析分别评价高血压病史、基线血压水平对主要心血管事件的影响;用多变量Cox回归分析模型识别主要心血管事件发生的预测因素.结果 本研究共纳入2016例房颤患者,全部患者平均收缩压/舒张压分别为(131.9±23.3)/(79.9±14.7)mm Hg(1 mm Hg=0.133 kPa);既往高血压病史的患者有1118例(55.5%),其中在高血压患者中,接受抗高血压治疗的比例高达91.1%.1年随访时的主要心血管事件发生共314例(15.6%),其中高血压病史组191例(17.1%),无高血压病史组123例(13.7%).对主要心血管事件作单变量Cox回归分析的结果显示,患者既往高血压病史、基线收缩压水平(连续变量)是1年随访主要心血管事件发生的危险因素(HR=1.269,95% CI:1.012~1.592,P=0.039;HR=1.005,95%CI:1.000 ~1.010,P=0.042),而基线舒张压水平(连续变量)无统计学意义(HR=0.998,95%CI:0.991 ~1.006,P=0.698).多变量Cox回归模型校正其他因素后,高血压病史分组及基线收缩压水平、舒张压水平对1年主要心血管事件的发生并不具有独立预测价值.此外,多变量Cox回归模型分析显示年龄、心力衰竭史、卒中史是房颤患者1年随访主要心血管事件发生的独立预测因素.结论 年龄、心力衰竭史、卒中史是房颤患者1年随访发生主要心血管事件的预测因素. Objective To explore the impact of hypertension history and baseline blood pressure levels on cardiovascular outcomes in Chinese emergency atrial fibrillation patients during 1 year follow- up. Methods This prospective study consecutively enrolled patients presenting to an emergency department with atrial fibrillation from 20 hospitals in China during November 2008 to October 2011. Baseline data and treatment regimen were recorded, all patients were followed up for one year, and major cardiovascular events (MACE including cardiovascular death, stroke, myocardial infarction, and non central nervous systemic embolism)were recorded. Patients were divided into hypertension history group and non-hypertension history group. Univariate Cox analysis was evaluated hypertension history, baseline blood pressure on major cardiovascular events. Multivariate Cox analysis recognized risk factors for major cardiovascular events. Results A total of 2016 atrial fibrillation patients were enrolled, and the average systolic blood pressure and diastolic blood pressure were ( 131.9 -+ 23.3) mm Hg( 1 mm Hg = 0. 133kPa), (79. 9 + 14. 7) mm Hg respectively. 1118 patients (55.5%) had a history of hypertension, and about 91.1% hypertension patient received antihypertensive treatment. Major cardiovascular events occurred in 314 cases ( 15.6% ) among 1 year follow up, and 191 cases ( 17. 1% ) among hypertension group and 123 cases ( 13.7% ) among non-hypertension group. Univariate Cox regression analysis of prognostic factors for major cardiovascular events showed that hypertension history and baseline systemic blood pressure were risk factors (HR=1.269, 95%CI: 1.012-1.592, P=0.039; HR =1.005, 95% CI- 1.000- 1.010, P=0.042). Multivariate Cox regression model analysis, adjusted others risk factors, showed that hypertension history, baseline systolic pressure levels, and baseline diastolic blood pressure did not have independent predictive value for major cardiovascular events. Moreover, multivariate Cox regression analysis showed that age, history of heart failure, history of stroke were independent prognostic factor for one year follow-up of major cardiovascular events in atrial fibrillation patients. Conclusion Age, history of heart failure, history of stroke were independent predictor for 1 year major cardiovascular events in Chinese emergency atrial fibrillation patients.
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2013年第11期911-915,共5页 Chinese Journal of Cardiology
关键词 心房颤动 血压 心血管事件 Atrial fibrillation Blood pressure Cardiovascular events
  • 相关文献

参考文献22

  • 1Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J,2013,34:2159-2219.
  • 2Le Heuzey JY, Breithardt G, Camm J, et al. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol, 2010,105:687-693.
  • 3Lawes CM, Vander HS, Rodgers A. Global burden of blood- pressure-related disease, 2001. Lancet,2008,371:1513-1518.
  • 4Carom AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010.
  • 5ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J,2012,33:2719- 2747.
  • 6Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRSfocused update on the management of patients with atrial fibrillation (updating the 2006 guideline ): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation, 2011, 123~ 104-123.
  • 7Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol,2005,45:705- 711.
  • 8Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA,2001,285:2864- 2870.
  • 9中国高血压防治指南2010[J].中华心血管病杂志,2011,39(7):579-616. 被引量:4632
  • 10周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1408

二级参考文献25

  • 1Wolf PA,Abbott RD,Kannel WB.Atrial fibrillation as an independent risk factor for stroke:the Framingham Study.Stroke,1991,22:983-988.
  • 2Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.Analysis of pooled data from five randomized controlled trials.Arch Intern Med,1994,154:1449-1457.
  • 3Connolly S,Pogue J,Hart R,et al.Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W):a randomised controlled trial.Lancet,2006,367:1903-1912.
  • 4Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation):developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Circulation,2006,114:e257-e354.
  • 5Go AS,Hylek EM,Borowsky LH,et al.Warfarin use among ambulatory patients with nonvalvular atrial fibrillation:the anticoagulation and risk factors in atrial fibrillation (ATRIA)study.Ann Intern Med,1999,131:927-934.
  • 6Hylek EM,Evans-Molina C,Shea C,et al.Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.Circulation,2007,115:2689-2696.
  • 7Shen AY,Yao JF,Brar SS,et al.Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation.J Am Coll Cardiol,2007,50:309-315.
  • 8Ansell J,Hirsh J,Hylek E,et al.Pharmacology and management of the vitamin K antagonists:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest,2008,133:160S-198S.
  • 9Anderson JL,Home BD,Stevens SM,et al.Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.Circulation,2007,116:2563-2570.
  • 10Boos CJ,Lip GY.Ximelagatran:an eulogy.Thromb Res,2006,118:301-304.

共引文献6042

同被引文献91

  • 1李苏红,高修仁.高血压患者24小时平均心率与心血管重塑关系[J].中山大学学报(医学科学版),2006,27(B03):233-235. 被引量:2
  • 2Hijazi Z,Siegbahn A, Andersson U, et al. High - sensitivity tro- ponin I for risk assessment in patients with atrial fibrillation: In- sights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial [J]. Circulation, 2014, 129(6) : 625 - 634.
  • 3Daugherty SL, Masoudi FA, Zeng C, et al. Sex differences in cardiovascular outcomes in patients with incident hypertension [J]. [J]Hypertens, 2013,31 (2), 271 - 277.
  • 4Lip GY, Frison L, Grind M. Effect of hypertension on anticoagula: ted patients with atrial fibrillation [J]. Eur Heart J, 2007, 28(9) 752 - 759.
  • 5Tenekecioglu E,Agca FV, Ozluk OA, et al. Disturbed left atrial function is associated with paroxysmal atrial fibrillation in hyper- tension [J]. Arq Bras Cardiol,2014,102(3) : 253- 262.
  • 6Bevc S,Purg D, Turn ek N, et al. Ankle- brachial index and cardiovascular mortality in nondiabetic hemodialysis patients [J]. Ther Apher Dial,2013, 17(4) :373- 377.
  • 7Wang JG, Staessen JA, Franklin SS, et at. Systolic and diastolic blood pressure lowering as determinants of cardiovascular out- comer [J]. Hypertension, 2005,45(9) : 907 - 913.
  • 8The AFFIRM investigators.A comparison of rate control and rhythm control in patients with atrial fibrillation[J].N Engl JMed, 2002,347: 1 825.
  • 9Issac TT, Dokainish H, Lakkis NM.Role of inflammation in initiation and perpetuation of atrial fibrillation: A sys- tematic review of the published data[J].J Am Coll Cardi- o/,2007,50(12): 2 021.
  • 10瞿且,2014版心衰诊疗指南肯定NT-proBNP的临床应用价值[EB/OL].(2014-07-31)[2014-09-05].http://www.njcnmc.com/manage/News-view.asp?NewslD=430.

引证文献9

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部